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cytopenia (26%/23%) and anemia (10%/0%). Nonhemato-
logical toxicity was rarely severe.  Conclusion: Combination 
chemotherapy with gemcitabine and carboplatin is an ef-
fective and generally well-tolerated treatment option for 
 intensively pretreated patients with MBC. Due to a consid-
erable incidence of severe thrombocytopenia it would be 
reasonable to consider starting gemcitabine at the lower 
dose level of 800 mg/m 2 .  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 As anthracycline- and also taxane-based regimens 
have become a standard of care for patients with primary 
breast cancer in the neoadjuvant and adjuvant setting, 
the number of patients who have already been exposed to 
these drugs in the metastatic stage is increasing. Hence, 
the evaluation of alternative treatment strategies not 
cross-resistant to anthracyclines or taxanes is mandatory. 
At the same time, it is important to ensure that efficacy 
is improved at the lowest cost to quality of life.
 Gemcitabine as a single agent has induced overall re-
sponse rates of 0–37% in first-line treatment, whereas the 
response rates in the second- or third-line therapy were 
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 Abstract 
 Background: Patients with metastatic breast cancer (MBC) 
are increasingly exposed to anthracyclines and taxanes ei-
ther during treatment of primary breast cancer or during ini-
tial therapy of metastatic disease. The combination of gem-
citabine and carboplatin was therefore investigated as an 
anthracycline- and taxane-free treatment option.  Patients 
and Methods: MBC patients previously treated with chemo-
therapy were enrolled in a multicenter phase II study. Treat-
ment consisted of gemcitabine (1,000 mg/m 2 i.v. on days 1 
and 8) and carboplatin (AUC 4 i.v. on day 1) applied every 
3 weeks.  Results: Thirty-nine patients were recruited, and a 
total of 207 treatment cycles were applied with a median of 
5 cycles per patient. One complete response and 11 partial 
responses were observed for an overall response rate of 31% 
(95% CI: 17–48%). Twelve patients (31%) had stable disease. 
Median time to progression was 5.3 months (95% CI: 2.6–6.7 
months) and median overall survival from start of treatment 
was 13.2 months (95% CI: 8.7–16.7 months). Grade 3/4 hema-
tological toxicity included leukopenia (59%/5%), thrombo-
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26 and 13%  [1–5] . In studies limited to second- or third-
line therapy after anthracycline and/or taxane exposure, 
response rates of 0–29% and median time to progression 
of 2– 6 months were reached  [3–5] .
 Gemcitabine is an excellent choice for combination 
therapy because of its unique mechanism of action and 
its favorable profile of side effects. The combination of 
gemcitabine and cisplatin was shown to be effective in 
several trials, inducing response rates between 30 and 
52% in patients pretreated with taxanes and/or anthracy-
clines  [6–10] .
 To improve on tolerability and feasibility of the regi-
men, carboplatin may be the more appropriate choice for 
treatment of metastatic disease. In four phase II trials of 
previously untreated patients with metastatic breast can-
cer (MBC), single agent carboplatin induced objective re-
sponse rates between 8 and 35%  [11–14] . Studies per-
formed in various solid tumor types indicate comparable 
activity of cisplatin and carboplatin  [15, 16] .
 It appears that resistance to platinum salts is induced 
by pretreatment, possibly by an upregulation of DNA re-
pair. Gemcitabine, a known inhibitor of DNA repair, 
may overcome this form of resistance and thus provides 
an excellent rationale for the combination of both agents. 
Exposure to platinum salts causes an activation of DNA 
repair polymerases and thereby enhances the incorpo-
ration of gemcitabine triphosphates into DNA repair 
patches. Once integrated into DNA, gemcitabine is not 
readily recognized and excised by proofreading exonu-
cleases and may trigger signaling pathways leading to 
apoptosis.
 Several considerations support the use of gemcitabine 
and a platinum salt in the salvage treatment of MBC. 
First, in vitro studies indicate additive or synergistic ac-
tivity which was most pronounced in platinum-resistant 
cell lines and was found to be due to an increased forma-
tion and an impaired repair of platinum-DNA adducts 
 [17, 18] . Second, gemcitabine and carboplatin are usually 
not included into adjuvant or neoadjuvant chemothera-
py. Therefore, resistance to either drug is unlikely to oc-
cur. Third, studies investigating the combination have 
shown minimal overlapping toxicity suggesting an ac-
ceptable toxicity profile even in intensively pretreated pa-
tients  [4, 19–21] . Finally, the addition of trastuzumab to 
gemcitabine/carboplatin might form an effective triplet 
combination  [22] . 
 The present multicenter phase II study was aimed
to evaluate the efficacy and tolerability of gemcitabine ap-
plied on days 1 and 8 plus carboplatin applied on day 1 
every 3 weeks in previously treated patients with MBC.
 Patients and Methods 
 Patient Population 
 Thirty-nine patients with histologically confirmed MBC were 
recruited to participate in a study with a treatment protocol ap-
proved by the local ethics committee. All patients were required 
to give written informed consent prior to study entry.
 Prior treatment with chemotherapy, hormonal therapy, im-
munotherapy or local radiotherapy was allowed. Patients were 
required with at least one bidimensionally measurable lesion out-
side a previous radiation port. Other eligibility criteria included 
age  6 18 years, Karnofsky performance status  6 70%, minimal 
life expectancy of 12 weeks, and adequate hematological, renal, 
cardiac and hepatic function [leukocyte count  6 3.0  ! 10 9 /l or 
absolute neutrophil count  6 2  ! 10 9 /l; platelet count  6 100  ! 
10 9 /l; hemoglobin  6 8 g/dl; total serum bilirubin  ^  1.25  ! upper 
limit of normal (ULN) in the absence of liver metastasis or  ^  3.0 
 ! ULN in the presence of liver metastasis; transaminase (ALT, 
AST) level  ^  3  ! ULN in the absence of liver metastasis or  ^  5 
 ! ULN in the presence of liver metastasis; alkaline phosphatase 
level  ^  2.5  ! ULN]. Creatinine clearance was required to exceed 
60 ml/min.
 Patients were not eligible for study enrolment if they were 
pregnant, lactating or refused effective contraception, and if they 
had bone metastasis only, known brain metastases or a secondary 
malignancy, history of another primary malignant disease other 
than in situ carcinoma of the uterine cervix or adequately treated 
basal cell skin cancer, active infection or any other concomitant 
severe clinical condition making implementation of the protocol 
including prehydration difficult. Administration of other cyto-
toxic, immune or hormonal agents or radiation therapy was not 
permitted during the study, with the exception of contraceptives, 
corticosteroids given as antiemetic treatment, or local palliative 
radiation.
 Patient Assessment 
 Patients were evaluated on a regular basis during treatment. 
The following assessments were performed before each 3-week 
cycle: physical examination, complete blood count, serum chem-
istry, and assessment of toxicities. During the initial phase of 
treatment, complete blood counts were performed twice weekly 
to determine the nadir values. If the hematological values had not 
recovered by the time of scheduled treatment, the complete blood 
count was repeated every week until recovery of leukocyte count 
to 3.0  ! 10 9 /l and platelets to  6 100  ! 10 9 /l.
 Baseline tumor assessment was performed within 2 weeks of 
the start of treatment using imaging procedures such as ultra-
sound, computerized tomography or magnetic resonance imag-
ing. Tumor assessments were repeated after every two cycles of 
therapy, applying the initially used imaging procedure. World 
Health Organization (WHO) and NCI-CTC criteria (3.0) were 
used for the assessment of tumor response and toxicity grading 
 [23, 24] .
 In addition, time to response (time from start of therapy to 
first documentation of objective response), duration of response 
(time from first documentation of objective response to first evi-
dence of progressive disease), time to tumor progression (time 
from start of therapy to first evidence of progressive disease or last 
follow-up), and survival (time from start of therapy to death) were 
measured (intent-to-treat).
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 Treatment Schedule 
 Treatment consisted of gemcitabine 1,000 mg/m 2 given as a 
30-min infusion on days 1 and 8 and carboplatin AUC 4 given as 
a 1-hour infusion on day 1 of a 3-week treatment cycle. Treatment 
was continued until disease progression or the occurrence of un-
acceptable toxicity.
 Dose adjustments were made on the basis of leukocyte and 
platelet counts on the day of treatment and clinical assessments 
of nonhematological toxicities. The doses of both drugs were re-
duced by 25% if the leukocyte count was between 2.5 and 3.0  ! 
10 9 /l, while the platelet count exceeded 100  ! 10 9 /l; if the leuko-
cyte count was less than 2.5  ! 10 9 /l  or the platelet count less than 
100  ! 10 9 /l, both drugs were omitted. Doses omitted on day 8 
were not replaced and the next cycle was given on time as sched-
uled but at reduced doses. If any toxicity  6 grade 3 except nausea/
vomiting or alopecia occurred, drug doses were reduced by 50%. 
If the patient tolerated the dose-modified treatment well, a re-in-
crease of the dose could be attempted in the following cycle. The 
use of hematopoietic growth factors was allowed in patients with 
prolonged hematopoietic recovery.
 Biometrical Analysis 
 The primary objective of the study was to determine the ob-
jective response rate to the study treatment. Secondary end 
points included time to progression, survival, and toxicity. Si-
mon’s optimal two-stage design  [25]  was used to ensure that the 
number of patients exposed to this therapy was minimized 
should the therapy prove ineffective. The study was planned to 
distinguish between a clinically uninteresting response rate of 
10% (null hypothesis) and a clinically interesting response rate 
of 30% (alternative hypothesis). With the type I error being 5% 
and the type II error 10%, 18 patients were to be enrolled during 
the first step and an additional 17 patients during the second 
step. If 2 or less responses occurred among the first 18 patients 
or 6 or less responses in the total population of 35 patients, the 
treatment had to be judged ineffective and enrolment stopped. 
If 7 or more responses were observed in the total patient popula-
tion, the study treatment was judged effective. Assuming a drop-
out rate of 10%, enrollment of a total of 39 patients was 
planned.
 The 95% confidence interval (CI) for the overall response rate 
was determined on the basis of the two-stage design. Time-to-
event end points were calculated according to the method of
Kaplan and Meier using the STATISTICA software  [24, 25] . Pa-
tients who received at least one treatment cycle were evaluable for 
toxicity, and those who had received at least two treatment cy-
cles or those who progressed after the first cycle were evaluable 
for response (intent-to-treat).
 Results 
 Patient Characteristics 
 Thirty-nine eligible patients were recruited from 12 
German centers. All patients were evaluable for re-
sponse, toxicity and survival. Median age was 60 years 
(range 29–77). All patients had previously received che-
motherapy, and 33 of them had received up to 5 prior 
Table 1. Baseline patient characteristics (n = 39)
Variable n %
Age, years
Median       60
      29–77Range
Karnofsky performance status, %
70–80 7 18
90–100 32 82
Hormone receptor status
ER or PgR positive 30 77
ER and PgR negative 8 21
Unknown 1 2
HER2 status (IHC)
0 17 43
1+ 7 18
2+ 2 5
3+ 10 26
Unknown 3 8
Metastatic sites
1 8 21
2 13 33
≥3 18 46
Sites of metastases
Liver 30 77
Lung 13 33
Lymph nodes 14 36
Bone 21 54
CNS 5 13
Other sites 23 59
Skin, soft tissue or nodal disease only 2 5
Bone disease only 0 0
Visceral 35 90
Tumor grading
G1 0 0
G2 17 44
G3 17 44
Unknown 5 13
Prior treatment
Any CT 39 100
CT for metastatic disease 33 85
Adjuvant CT 24 62
Taxane 26 67
Anthracycline 34 87
Anthracycline + taxane 25 64
Number of prior CT regimens for MBC
0 6 15
1 14 36
2 8 21
≥3 11 29
CT = Chemotherapy; ER = estrogen receptor; PgR = proges-
terone receptor; IHC = immunohistochemistry.
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chemotherapy regimens for metastatic disease. Twenty-
six patients (67%) had previously received anthracy-
clines and 25 patients (64%) both, an anthracycline- and 
a taxane-based regimen. Prior endocrine therapy in 
hormone receptor-positive patients had been applied to 
31 patients (80%). Twenty-six patients (67%) had re-
ceived tamoxifen, and 20 patients had received an aro-
matase inhibitor (51%). Thirty-five patients presented 
with visceral metastases (90%) and 31 patients (79.5%) 
had more than one metastatic site.
 Patient characteristics are shown in  table 1. 
 Treatment Delivery 
 A total of 207 cycles of gemcitabine and carboplatin 
were delivered. Patients received a median number of 5 
cycles (range: 1–12 cycles). Median duration of treatment 
was 3.8 months (range: 0.5–9.3 months). Dose reduc-
tions, delays and omissions occurred in 131 (63%), 65 
(31%) and 36 (17%) cycles, respectively.
 Response and Survival 
 All patients were evaluable for efficacy ( table 2 ). One 
patient achieved a complete response and 11 patients 
(28.2%) a partial response, for an objective response rate 
of 30.8% (95% CI: 17.0–47.6%). Overall, disease control 
rate (objective response plus stable disease) was 61.5% 
(95% CI: 44.6–76.6%). Disease stabilization was achieved 
in 12 patients (30.8%), lasting for more than 3 months in 
11 (28.2%) and for more than 6 months in 7 patients 
(17.9%).
 A detailed analysis of response with regard to baseline 
characteristics was undertaken ( table 3 ). Response rate 
was higher in hormone receptor-positive and HER2-neg-
ative patients. Moreover, a higher response rate was ob-
served in patients with one metastatic site only, with less 
than 3 prior treatment regimens for metastatic disease 
Table 2. Efficacy of gemcitabine plus carboplatin
Parameter Patients % 95% CI
CR 1 2.6
PR 11 28.2
SD 12 30.8
SD >3 months 11 91.7
SD >6 months 7 58.3
PD 12 30.8
ORR 12 31.0 17–48%
DCR (CR+PR+SD) 24 61.6
CR = Complete remission; PR = partial remission; SD = stable 
disease; PD = progressive disease; DCR = disease control rate.
Variable Total
patients
Overall response
patients % 95% CI
Prior CTs for MBC
0–2 (1st line, 2nd line) 28 11 39.3 21.5–59.4
>2 (beyond 2nd line) 11 1 9.1 0.2–41.3
Metastatic sites
1 8 5 62.5 24.5–91.5
≥2 31 7 22.6 9.6–41.1
Pretreatment with anthracycline and/or taxane
With anthracycline
With taxane
With both
34
26
25
11
7
7
32.4
26.9
28.0
17.4–50.5
11.6–47.8
12.1–49.4
Pretreatment without A/T 14 5 35.7 12.8–64.9
Hormone receptor status
ER and/or PgR positive 30 10 33.3 17.3–52.8
ER and PgR negative 9 2 22.2 2.8–60.1
HER2 status (IHC, DAKO)
Positive (3+) 10 2 20.0 2.5–55.6
Negative (0, 1+, 2+, unknown) 29 10 34.5 17.9–54.3
CT = Chemotherapy; A = anthracycline; T = taxane; ER = estrogen receptor; PgR = 
progesterone receptor; IHC = immunohistochemistry.
Table 3. Response rates by baseline
characteristics
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and without prior treatment containing an anthracycline 
and/or a taxane.
 The median time to first observation of an objective 
response was 2.6 months (95% CI: 1.3–5.1 months). Me-
dian duration of response was 3.3 months (95% CI: 3.0–
5.8 months), and median time to progression was 5.3 
months (95% CI: 2.6–6.7 months). The median overall 
survival was 13.2 months (95% CI: 8.7–16.7 months). Time 
to progression and overall survival are shown in  figure 1 . 
The time-to-event parameters are listed in  table 4 .
 Toxicity 
 The predominant hematological toxicity was leukope-
nia grade 3/4 which occurred in 25 (64%) of the patients 
and 26% of the applied cycles. Four patients (10%) expe-
rienced febrile neutropenia. Growth factor support was 
applied in 15 patients (38%). Grade 3/4 thrombocyto-
penia occurred in 19 patients (49%) and 23% of cycles, 
respectively. Anemia grade 3/4 was less frequent (10% of 
patients, 3% of cycles).
 Nonhematological toxicity was considered mild to 
moderate. Grade 4 nonhematological toxicity was ob-
served in 8 patients (21%) including elevation of serum 
transaminases (3% of patients, 0.5% of cycles), elevation 
of   -glutamyltransferase (8% of patients, 1.5% of cycles) 
and dyspnea (8% of patients, 0.5% of cycles). No grade 4 
neurotoxicity and nephrotoxicity were observed. Neuro-
toxicity grade 1 or 2 was observed in 12 patients (31%), 
Table 4. Time-to-event parameters
Parameter Median
months
95% CI 
months
Remission and progression
Time to remission 2.6 1.3–5.1
Duration of remission 3.3 3.0–5.8
Duration of stable disease 6.8 5.7–7.9
Time to progression 5.3 2.6–6.7
Survival
Overall survival 13.2 8.7–16.7
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 Fig. 1. Time to progression (TTP, ––––) and overall survival (OS,  
– – –).  
Table 5. Toxicities (number and % of patients)
Evaluable
patients
WHO grade
1 2 3 4
n % n % n % n %
Hematological toxicity
Leukopenia 39 1 3 12 31 23 59 2 5
Febrile neutropenia 39 0 0 2 5 1 3 1 3
Thrombocytopenia 39 9 23 8 21 10 26 9 23
Anemia 39 10 26 25 64 4 10 0 0
Nonhematological toxicity
Alopecia 39 6 15 16 41 3 8 0 0
Nausea/vomiting 39 19 49 16 41 0 0 0 0
Asthenia 39 15 38 6 15 0 0 0 0
Neurotoxicity 39 8 21 4 10 0 0 0 0
Nephrotoxicity 39 7 18 1 3 1 3 0 0
Alkaline phosphatase 39 16 41 4 10 4 10 0 0
AST 39 21 54 12 31 2 5 1 3
ALT 39 16 41 11 28 5 13 0 0
Bilirubin 39 2 5 2 5 4 10 0 0
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and nephrotoxicity grade 1–2 was documented in 8 pa-
tients (21%). Hematological and nonhematological tox-
icities are shown in  table 5 .
 Discussion 
 With the increasing use of anthracycline- and taxane-
based regimens in the adjuvant and neoadjuvant setting 
and their established application in the treatment of the 
advanced and metastatic stages of breast cancer, there is 
a clear need for non-cross-resistant further-line regi-
mens. While there is no established standard of chemo-
therapy for anthracycline- and taxane-pretreated pa-
tients, capecitabine has become a widely accepted agent 
in this treatment setting. In phase II and III trials re-
sponse rates in the range of 26–52% and time to progres-
sion of 3.6–8.9 months were reported  [26–30] .
 The preclinical rationale for a combination of gem-
citabine with a platinum analog is supported by the syner-
gistic interaction of both agents  [17, 18, 31] . Several clinical 
studies performed with various schedules have demon-
strated that the combination of gemcitabine and cisplatin 
is highly active not only in first-line treatment, but also in 
patients previously exposed to anthracyclines and/or tax-
anes ( table 6 ). While a formal comparison of carboplatin 
and cisplatin has never been performed in MBC, the avail-
able evidence suggests a better tolerability of carboplatin 
 [32] . Due to its lower emetogenic and nephrotoxic poten-
tial carboplatin may be specifically preferred in intensive-
ly pretreated patients. Moreover, time-consuming hydra-
tion regimens can be avoided with carboplatin.
Table 6. Overview of clinical trials regarding treatment of MBC patients with gemcitabine and platinum salts either as single agents 
or in combination
Reference n Regimen OR, % TTP, months OS, months
1st-line gemcitabine (GEM)
Blackstein et al. [2] 39 GEM 73.1 5.1 21.1
2nd-line gemcitabine (GEM)
Brodowicz et al. [3] 25 GEM 2nd-line (n = 9); 22 5.1 12.6
3rd-line (n = 16) 12 3.5 7.5
Spielmann et al. [5] 47 GEM 29 8.1 n.a.
Carmichael et al. [34] 40 GEM 1st-/2nd-line 25 1.9 11
Smorenburg et al. [35] 23 GEM 0 1.9 7.8
1st-line carboplatin (CBDA)
Kolaric and Vukas [11] 20 carboplatin 20 n.a. n.a.
2nd-line carboplatin (CBDA)
Martin et al. [12, 13] 34 carboplatin 35 8 n.a.
O’Brien et al. [14] 40 carboplatin 8 4.5 n.a.
1st-line (n = 13) 33
2nd-line (n = 27)
1st-line GEM/cisplatin
Mohran [9] 25 GEM/cisplatin 54.5 n.a. 14.8
Fuentes et al. [10] 46 GEM/cisplatin 81 14.9 27.9
Alauddin and Shaharyar [36] 30 GEM/cisplatin 76.7 n.a. n.a.
2nd-line GEM/cisplatin or carboplatin
Burch et al. [37] 58 GEM/cisplatin 29 (high dose) 7.7 16.9
(2 dose levels) 32 (low dose) 6.5 13.5
Seo et al. [6] 30 GEM/cisplatin 30 7 15
Heinemann et al. [7] 38 GEM/cisplatin 40 6 13.5
Chitapanarux et al. [8] 30 GEM/cisplatin 52 n.a. n.a.
Moura et al. [38] 74 GEM/cisplatin 30 7.7 18.3
Nasr et al. [21] 30 CEM/carboplatin 30 5.1 n.a.
Nagourney et al. [20] 12 GEM/carboplatin 50 5 n.a.
Latini et al. [19] 13 GEM/carboplatin 69.2 n.a. n.a.
Silva et al. [33] 19 GEM/carboplatin 21.5 n.a. 7.5
TTP = Time to progression; OS = overall survival; GEM = gemcitabine; n.a. = not available.
 Gemcitabine/Carboplatin for MBC Oncology 2007;73:407–414 413
 The present study evaluated a 3-week regimen, where 
gemcitabine was applied on days 1 and 8, while carbopla-
tin was given on day 1. Most patients had undergone pre-
vious treatment with anthracyclines (67%) and/or tax-
anes (64%). The efficacy of gemcitabine plus carboplatin 
(overall response rate 31%, 95% CI: 17–48%) reached the 
predefined endpoint of a clinically relevant activity. The 
median duration of most responses and disease stabiliza-
tions was 3.3 and 6.8 months, respectively. The median 
time to progression was 5.3 months resulting in a median 
overall survival of 13.2 months.
 Comparable results have also been reported by Nasr et 
al.  [21] who investigated a schedule where gemcitabine 
(1,000 mg/m 2 , days 1 + 8) and a greater dose of carbopla-
tin (AUC 5 on day 1) were applied in a 3-week regimen. 
The combination was given to 30 MBC patients as a sec-
ond-line treatment. The overall response rate was 30% 
and median time to progression was 4.8 months. Main 
grade 3/4 hematological toxicities were neutropenia in 
50% of patients (20% of whom had febrile neutropenia), 
anemia in 26.6% and thrombocytopenia in 30% of pa-
tients.
 The same schedule was evaluated by Silva et al.  [33]  in 
19 comparably pretreated MBC patients yielding an over-
all response rate of 21.5% and a median overall survival 
of 7.5 months. Main hematological toxicities included 
anemia (21% of patients), neutropenia (21%), and throm-
bocytopenia in 5% of patients.
 Nagourney et al. [20] reported a ‘repeating doublet’ 
regimen, where gemcitabine (800 mg/m 2 ) and carbopla-
tin (AUC 2) were both applied on days 1 and 8 of a 3-week 
regimen. Ten evaluable patients with first or second re-
currence of MBC had received the schedule with an over-
all response rate of 50% (including 1 complete response) 
and a median time to progression of 5 months (range 2–
20 months). Most commonly reported grade 3 and 4 side 
effects were neutropenia (60% of patients) and thrombo-
cytopenia (40% of patients).
 The treatment-associated toxicity profile in our study 
was generally acceptable. Hematological toxicity (grade 
3 and 4), mainly leukopenia and thrombocytopenia, oc-
curred in 26 and 23% of the applied cycles, respectively. 
The rate of febrile neutropenia was low (6% of patients) 
as compared to an incidence of 20% in the study by Nasr 
et al.  [21] . As a consequence, a median of five cycles could 
be administered without significant delays or dose re-
ductions. Nevertheless, 38% of the patients required he-
matopoietic growth factor support. This is in part ex-
plained by the intensive pretreatment observed in most 
of the patients. Thus, for the considerable incidence of 
severe thrombocytopenia it would be reasonable to con-
sider starting gemcitabine at the lower dose level of 800 
mg/m 2 . Symptomatic adverse events such as nausea/
vomiting or asthenia were generally mild to moderate. 
There was no patient who developed renal dysfunction 
( 6 grade 2).
 Certainly, an optimal regimen of gemcitabine/carbo-
platin for intensively pretreated MBC patients has not 
been determined in a comparative fashion. It appears, 
however, that the application of carboplatin on day 1 may 
be preferred to the repeating doublet regimen since the 
latter was associated with a higher incidence of hemato-
logical toxicity (neutropenia 26 vs. 60%, thrombocytope-
nia 23 vs. 40%).
 In conclusion, the combination of gemcitabine plus 
carboplatin is a generally well-tolerated and effective reg-
imen that provided sustained disease control in inten-
sively pretreated breast cancer patients. Specifically after 
previous exposure to anthracyclines and/or the taxanes, 
this regimen can be considered as an active treatment op-
tion which offers a favorable balance between efficacy 
and tolerability.
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